NCT06493370招募中2 期
Intravenous Ascorbate Plus Gemcitabine/Carboplatin: a Novel and Cost-Effective Alternative with Evident Efficacy in Patients with Muscle Invasive Bladder Cancer
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 入组人数
- 48
- 试验地点
- 2
- 主要终点
- Post treatment pathological staging
研究概览
简要总结
This is a phase II, single arm, Simon two-stage design, trial, enrolling patients with cisplatin ineligible MIBC and/or those patients who decline cisplatin based NAC.
Assess rates of pathologic downstaging and quality of life in MIBC cisplatin-ineligible/declined patients when IVC is added to gemcitabine-carboplatin NAC.
详细描述
The investigator has hypothesized adding IVC to carbo/gem NAC will enhance pathological downstaging and improve QOL. The patients eligible for this study (cisplatin ineligible or declined with MIBC) typically proceed straight to cystectomy within 12 weeks of initial diagnosis.
In this study, participants will receive two cycles of gemcitabine/carboplatin, along with IVC and then proceed to cystectomy.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Ability of participant to understand this study, and participant willingness to sign a written informed consent
- •Consent to participate in biorepository protocol number GUB-BCR-001, KU IRB Approved HSC # STUDY00141546
- •Males and females age ≥ 18 years
- •ECOG Performance Status (PS) 0 - 2
- •Women of childbearing potential must have a negative serum pregnancy test 72 hours prior to initiating treatment.
- •Diagnosis/disease status Cisplatin-ineligible or declined muscle invasive bladder cancer. Cisplatin ineligibility will be defined based on Galsky criteria: CTCAE ver. 5.0 Grade 2 or greater peripheral neuropathy; CTCAE ver. 5.0 Grade 2 or greater hearing loss; Creatinine clearance estimated or calculated < 60 ml/min; NYHA class II or greater congestive heart failure
- •Adequate organ function, defined as follows: Absolute Neutrophil Count >1.5K/UL. (NOTE: Patients with established diagnosis of benign neutropenia are eligible to participate with ANC between 1000-1500 based on discretion of the treating physician.); Platelets >100K/UL; Hemoglobin ≥ 9 g/dL; Serum creatinine ≤ 1.5 x upper limit of normal (ULN) or calculated creatinine clearance ≥ 30 mL/min using the Cockcroft-Gault equation; Total bilirubin ≤ 2.0 x ULN; Aspartate aminotransferase (AST [SGOT]) and alanine aminotransferase (ALT [SGPT]) ≤ 2.5 x ULN unless liver metastases are present, in which case they must be ≤ 5 x ULN; Normal Glucose-6-phosphate dehydrogenase (G6PD) status
- •Women of child-bearing potential (WOCBP) and men with partners of child-bearing potential must agree not to donate sperm (men), to practice sexual abstinence or to use the forms of contraception listed in Child-Bearing Potential/Pregnancy section for the duration of study participation and for WOMEN: 6 months after EOT, MEN: 3 months after EOT following completion of therapy.
排除标准
- •Simultaneously enrolled in any therapeutic clinical trial
- •Current or anticipating use of other anti-neoplastic or investigational agents while participating in this study
- •Diagnosed with a psychiatric illness or is in a social situation that would limit compliance with study requirements
- •Is pregnant or breastfeeding. There is a potential for congenital abnormalities and for this regimen to harm breast feeding infants
- •Women of childbearing age expecting to conceive children while receiving study treatment and for 6 months after the last dose of study treatment. Men expecting to conceive children while receiving study treatment and for 3 months after the last dose of study treatment
- •Has a severe known allergic reaction to any excipient contained in the study drug formulation
- •Active Grade 3 or 4 (per the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE), Version 5.0109) viral, bacterial, or fungal infection within 2 weeks prior to the first dose of study treatment.
- •Uncontrolled intercurrent illness, including but not limited to, ongoing or active infection, symptomatic congestive heart failure, uncontrolled hypertension, unstable angina pectoris, cardiac arrhythmia, interstitial lung disease, serious chronic gastrointestinal conditions associated with diarrhea, as determined per treating physician.
- •Histology of pure adenocarcinoma, pure squamous cell carcinoma, or pure small cell carcinoma in the TURBT sample
- •Current consumption of tobacco products, patients may be asked to quit for 2 weeks prior to enrollment
- •If tobacco use is suspected at any point during the trial, cotinine level will be obtained
- •History of G6PD deficiency
- •History of oxalate renal calculi - per discretion of treating physician
研究组 & 干预措施
Intravenous ascorbic acid/vitamin C
Experimental
2 Cycles Carboplatin Day 1 and Gemcitabine Days 1 and 8 (NAC)
- Intravenous Vitamin C Days 1-28
干预措施: Intravenous ascorbic acid/vitamin C (Drug)
结局指标
主要结局
Post treatment pathological staging
时间窗: Approximately 10 to 12 weeks
To assess pathologic downstaging rate in MIBC cisplatin-ineligible patients when IVC is added to a gemcitabine/carboplatin NAC regimen. Pre and Post treatment specimen pathology results evaluated per American Joint Committee on Cancer (AJCC) staging guidelines.
次要结局
- To assess Quality of life (QOL)(Approximately 10 to 16 weeks)
- To measure Disease Free Survival (DFS)(Approximately 2 years)
- To measure Disease Specific Survival (DSS)(Approximately 2 years)
研究者
John Taylor
Director of Basic Urologic Research
University of Kansas Medical Center
研究点 (2)
Loading locations...
相似试验
招募中
2 期
Combined Therapy Using Gemcitabine and Cisplatin Chemotherapy, Lenvatinib and Adebrelimab for Patients With Advanced and Unresectable Intrahepatic CholangiocarcinomaIntrahepatic CholangiocarcinomaNCT06298968Nanfang Hospital, Southern Medical University38
招募中
2 期
Gemcitabine Hydrochloride, Cisplatin, Nab-Paclitaxel, and Durvalumab in Treating Patients With Locally Advanced or Metastatic Gallbladder CancerGallbladder Cancer UnresectableNCT06591650Fudan University33
已完成
2 期
Combination Gemcitabine, Carboplatin With or Without Trastuzumab in Patients With Metastatic Breast CancerBreast CancerNCT00193076SCRI Development Innovations, LLC96
Unknown
2 期
Cisplatin With Alimta or Gemcitabine in Long Infusion for MesotheliomaMesotheliomaNCT01281800Institute of Oncology Ljubljana72
已完成
1 期
A phase I/II study of Cisplatin, Amrubicin plus irradiation for Limited disease small cell lung cancersmall cell lung cancerJPRN-UMIN000005816agasaki Thoracic Oncology Group35